Table 2.
Associations between plasma tau species and Alzheimer’s disease neuropathology
| OR (95% CI) | AUC (95% CI) | |
|---|---|---|
| Total sample: 69 AD, 54 no AD | ||
| P-tau217/tau212–221 | 11.03 (4.93, 30.42) | 90.0 (84.1, 96.0) |
| P-tau217 | 27.00 (8.60, 112.33) | 89.8 (83.8, 95.8) |
| P-tau231 | 5.28 (2.61, 12.43) | 83.4 (75.6, 91.2) |
| P-tau205/tau195–209 | 4.07 (2.21, 8.49) | 82.1 (73.9, 90.2) |
| P-tau205 | 5.62 (2.57, 14.60) | 81.3 (73.2, 89.4) |
| P-tau181 | 3.02 (1.74, 5.84) | 79.0 (70.3, 87.6) |
| Tau195–209 | 2.47 (1.47, 4.66) | 78.1 (69.3, 86.9) |
| Tau212–221 | 1.85 (1.18, 3.15) | 72.6 (63.1, 82.1) |
| P-tau199 | 1.83 (1.15, 3.11) | 72.1 (62.4, 81.7) |
| P-tau202 | 1.70 (1.05, 2.91) | 71.1 (61.3, 80.9) |
| CDR < 1.0: 26 AD, 45 no AD | ||
| P-tau217 | 22.04 (5.57, 137.05) | 86.3 (76.7, 96.0) |
| P-tau217/tau212–221 | 8.34 (3.31, 27.35) | 85.6 (75.1, 95.9) |
| P-tau231 | 5.13 (2.17, 15.20) | 80.6 (69.3, 91.9) |
| P-tau205 | 7.06 (2.28, 27.98) | 77.1 (64.8, 89.4) |
| P-tau205/tau195–209 | 4.74 (1.79, 20.10) | 76.5 (63.5, 90.0) |
| P-tau181 | 2.37 (1.28, 4.94) | 71.3 (58.6, 84.0) |
| Tau195–209 | 2.65 (1.26, 6.67) | 72.8 (59.5, 86.1) |
| Tau212–221 | 1.65 (0.89, 3.39) | 64.0 (49.6, 78.4) |
| P-tau199 | 1.65 (0.82, 3.56) | 63.3 (48.6, 78.0) |
| P-tau202 | 1.50 (0.76, 3.09) | 63.3 (48.7, 77.9) |
| CDR ≥ 1.0: 43 AD, 9 no AD | ||
| P-tau217 | 189.34 (9.76, 26,020.65) | 96.1 (90.7, 100.0) |
| P-tau217/tau212–221 | 54.82 (5.32, 5625.03) | 96.1 (90.1, 100.0) |
| P-tau231 | 19.96 (2.69, 691.77) | 92.2 (84.3, 100.0) |
| P-tau205/tau195–209 | 4.74 (1.79, 20.08) | 91.9 (83.8, 100.0) |
| P-tau205 | 5.66 (1.68, 36.66) | 90.1 (81.1, 99.1) |
| P-tau181 | 17.42 (2.75, 372.20) | 89.2 (78.7, 99.7) |
| Tau195–209 | 2.12 (0.97, 6.31) | 84.4 (72.7, 96.0) |
| Tau212–221 | 2.63 (1.07, 9.39) | 81.7 (69.1, 94.3) |
| P-tau199 | 2.03 (0.97, 5.65) | 80.2 (66.4, 94.0) |
| P-tau202 | 2.17 (0.91, 6.92) | 81.1 (68.4, 93.7) |
Binary logistic regression examined the association between plasma tau levels and intermediate to high Alzheimer’s disease neuropathologic change (per NIA-Reagan criteria). Models controlled for age at death, years between last blood draw and death, sex, and APOE ε4 carrier status. The AUC statistics were calculated using predicted probabilities from the binary logistic regression. Biomarkers are presented in rank order of their AUC statistic
AD Alzheimer’s disease, CDR clinical dementia rating (CDR) dementia staging instrument, OR odds ratio, CI confidence interval, p-tau phosphorylated tau